214 related articles for article (PubMed ID: 31383485)
1. Spontaneously released Neisseria meningitidis outer membrane vesicles as vaccine platform: production and purification.
Gerritzen MJH; Salverda MLM; Martens DE; Wijffels RH; Stork M
Vaccine; 2019 Nov; 37(47):6978-6986. PubMed ID: 31383485
[TBL] [Abstract][Full Text] [Related]
2. Surface display of a borrelial lipoprotein on meningococcal outer membrane vesicles.
Salverda ML; Meinderts SM; Hamstra HJ; Wagemakers A; Hovius JW; van der Ark A; Stork M; van der Ley P
Vaccine; 2016 Feb; 34(8):1025-33. PubMed ID: 26801064
[TBL] [Abstract][Full Text] [Related]
3. High dissolved oxygen tension triggers outer membrane vesicle formation by Neisseria meningitidis.
Gerritzen MJH; Maas RHW; van den Ijssel J; van Keulen L; Martens DE; Wijffels RH; Stork M
Microb Cell Fact; 2018 Oct; 17(1):157. PubMed ID: 30285743
[TBL] [Abstract][Full Text] [Related]
4. Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.
Gorringe AR; Taylor S; Brookes C; Matheson M; Finney M; Kerr M; Hudson M; Findlow J; Borrow R; Andrews N; Kafatos G; Evans CM; Read RC
Clin Vaccine Immunol; 2009 Aug; 16(8):1113-20. PubMed ID: 19553555
[TBL] [Abstract][Full Text] [Related]
5. Outer membrane vesicles as platform vaccine technology.
van der Pol L; Stork M; van der Ley P
Biotechnol J; 2015 Sep; 10(11):1689-706. PubMed ID: 26912077
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.
Sanders H; Feavers IM
Expert Rev Vaccines; 2011 Mar; 10(3):323-34. PubMed ID: 21434800
[TBL] [Abstract][Full Text] [Related]
7. Sulfate depletion triggers overproduction of phospholipids and the release of outer membrane vesicles by Neisseria meningitidis.
Gerritzen MJH; Martens DE; Uittenbogaard JP; Wijffels RH; Stork M
Sci Rep; 2019 Mar; 9(1):4716. PubMed ID: 30886228
[TBL] [Abstract][Full Text] [Related]
8. Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870.
Hou VC; Koeberling O; Welsch JA; Granoff DM
J Infect Dis; 2005 Aug; 192(4):580-90. PubMed ID: 16028126
[TBL] [Abstract][Full Text] [Related]
9. Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential.
O'dwyer CA; Reddin K; Martin D; Taylor SC; Gorringe AR; Hudson MJ; Brodeur BR; Langford PR; Kroll JS
Infect Immun; 2004 Nov; 72(11):6511-8. PubMed ID: 15501782
[TBL] [Abstract][Full Text] [Related]
10. Proteomic analysis of Neisseria lactamica and N eisseria meningitidis outer membrane vesicle vaccine antigens.
Vaughan TE; Skipp PJ; O'Connor CD; Hudson MJ; Vipond R; Elmore MJ; Gorringe AR
Vaccine; 2006 Jun; 24(25):5277-93. PubMed ID: 16682101
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.
Finney M; Vaughan T; Taylor S; Hudson MJ; Pratt C; Wheeler JX; Vipond C; Feavers I; Jones C; Findlow J; Borrow R; Gorringe A
Hum Vaccin; 2008; 4(1):23-30. PubMed ID: 17921703
[TBL] [Abstract][Full Text] [Related]
12. Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants.
van der Ley P; van den Dobbelsteen G
Hum Vaccin; 2011 Aug; 7(8):886-90. PubMed ID: 21785281
[TBL] [Abstract][Full Text] [Related]
13. Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin.
Koeberling O; Seubert A; Granoff DM
J Infect Dis; 2008 Jul; 198(2):262-70. PubMed ID: 18505380
[TBL] [Abstract][Full Text] [Related]
14. Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine.
Oftung F; Naess LM; Wetzler LM; Korsvold GE; Aase A; Høiby EA; Dalseg R; Holst J; Michaelsen TE; Haneberg B
Infect Immun; 1999 Feb; 67(2):921-7. PubMed ID: 9916109
[TBL] [Abstract][Full Text] [Related]
15. Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.
Jessouroun E; da Silveira IF; Larangeira AP; Pereira S; Fernandes SA; Rabinovitch L; Frasch CE; Castro-Faria-Neto HC; Bozza PT
Vaccine; 2004 Jun; 22(20):2617-25. PubMed ID: 15193387
[TBL] [Abstract][Full Text] [Related]
16. Exploitation of
Petousis-Harris H; Radcliff FJ
Front Immunol; 2019; 10():683. PubMed ID: 31024540
[TBL] [Abstract][Full Text] [Related]
17. Induction of immune responses by purified outer membrane protein complexes from Neisseria meningitidis.
Marzoa J; Sánchez S; Costoya L; Diéguez-Casal E; Freixeiro P; Brookes C; Allen L; Taylor S; Gorringe AR; Ferreirós CM; Criado MT
Vaccine; 2012 Mar; 30(13):2387-95. PubMed ID: 21911024
[TBL] [Abstract][Full Text] [Related]
18. Immuno-proteomic analysis of human immune responses to experimental Neisseria meningitidis outer membrane vesicle vaccines identifies potential cross-reactive antigens.
Williams JN; Weynants V; Poolman JT; Heckels JE; Christodoulides M
Vaccine; 2014 Mar; 32(11):1280-6. PubMed ID: 24486354
[TBL] [Abstract][Full Text] [Related]
19. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them.
Holst J
Hum Vaccin; 2007; 3(6):290-4. PubMed ID: 17712231
[TBL] [Abstract][Full Text] [Related]
20. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
